Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 118.58% from the stock’s current price.

Separately, Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Down 1.7 %

NASDAQ:ATXS traded down $0.13 during mid-day trading on Monday, hitting $7.32. 34,277 shares of the stock traded hands, compared to its average volume of 201,305. The business’s 50-day moving average price is $9.85 and its 200 day moving average price is $10.70. The company has a market cap of $413.10 million, a PE ratio of -3.50 and a beta of 0.70. Astria Therapeutics has a 12-month low of $6.94 and a 12-month high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds have recently made changes to their positions in ATXS. Quest Partners LLC lifted its position in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in Astria Therapeutics in the 3rd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new stake in Astria Therapeutics during the 3rd quarter valued at $155,000. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics during the 2nd quarter valued at $171,000. Finally, Intech Investment Management LLC purchased a new position in shares of Astria Therapeutics in the 3rd quarter worth $228,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.